Issue 115

Alcohol-use disorder, addiction and Awakn’s expansion across the Atlantic

Awakn Life Sciences announced that its Phase III clinical trial with ketamine-assisted therapy for the treatment of alcohol-use disorder would be delivered across seven NHS sites in the UK.

Furthermore, two-thirds of the study will be funded by UK government agencies, in recognition of the treatment’s potential efficacy and its socioeconomic impact. It is estimated over two million UK adults have serious alcohol problems, but only one in five receive treatment.

To discuss alcohol-use disorder, addiction and Awakn’s expansion across the Atlantic, PSYCH spoke with Kevin Lorenz, US Head of Commercial Development.

READ MORE

PSYCHEDELIC THERAPY FOR GAMBLING ADDICTION

A University of Exeter study, funded by Awakn Life Sciences, will explore ketamine-assisted therapy in the treatment of gambling addiction.

Read More

PSYCHEDELIC MEDICINES IN THE TREATMENT OF TBI

Dr Lewis at the Toronto Centre for Neurology spoke with Psychedelic Health on treating brain injuries with psychedelic medicine.

Read More

BUSINESS AND INVESTMENT

Revive Therapeutics raises C$4.3m in private placement.

Numinus reports Q1 2023 financial results.

The legalisation of psilocybin services in Colorado.

Survey finds over 65s open to microdosing psychedelic medicine.

GH Research shares results from depression study with 5-MeO-DMT.

Ceruvia doses first patient in BOL-148 clinical trial.

Cybin shares results from Kernel Flow feasibility study.

Field Trip launches online integration therapy platform.

Irwin Naturals and Braxia to launch clinical research services.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Super Early Bird tickets on sale for £249 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

Risks and benefits of psilocybin in treating bipolar disorder.

Impact of blinding challenges in psychedelic research.

The therapeutic potential of microdosing psychedelic medicine.

The market for psychedelic-assisted therapy is expected to be worth over US$2.5 billion in 2024.

The Psychedelics as Medicine Report: Fourth Edition provides industry intelligence, empowering investors to make informed decisions.

COMPLIMENTARY DOWNLOAD

REGULATION AND LEGISLATION

Illinois lawmaker files bill to legalise psychedelic-assisted therapy.

Lawmakers in Washington file new psilocybin services bill.

The state-wide regulation of psilocybin in the US.

Regulating therapists for psychedelic healthcare in Alberta.

New Hampshire lawmaker files bill to legalise psychedelic medicine.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to engage with an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

Mental health concerns among UK firefighters.

Correlation between mental health conditions and ADHD.

Store selling MDMA, cocaine and heroin to open in Vancouver.

The impact of the cost-of-living crisis on mental health in the UK.

Do you know a spokesperson who could provide insights on the future of psychedelic healthcare?

Previous symposium speakers include:

  • Rick Doblin – Founder, MAPS
  • Cosmo Feilding Mellen – CEO, Beckley Psytech
  • Carol Routledge – Chief Medical and Scientific Officer, Small Pharma
  • MP Crispin Blunt – Chair, The Conservative Drug Policy Reform Group
SPEAKING OPPORTUNITIES
Partner with us